Patents Assigned to 1200 Pharma LLC
  • PRMT5 inhibitors and uses thereof
    Patent number: 12583859
    Abstract: The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 24, 2026
    Assignees: California Institute of Technology, 1200 Pharma LLC, The Regents of the University of California
    Inventors: Brendan M. O'Boyle, Corey M. Reeves, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Steven J. Wittenberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • CDK inhibitors and uses thereof
    Patent number: 12486280
    Abstract: The present disclosure provides compounds and compositions that are CDK inhibitors selective for CDK4 and/or CDK6, and methods of use thereof.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: December 2, 2025
    Assignees: California Institute of Technology, The Regents of the University of California, 1200 Pharma LLC
    Inventors: Brendan M. O'Boyle, Justin A. Hilf, Scott C. Virgil, Alexander W. Sun, Brian M. Stoltz, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Michael D. Bartberger
  • ERK inhibitors and uses thereof
    Patent number: 12428416
    Abstract: The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 30, 2025
    Assignees: California Institute of Technology, 1200 Pharma LLC, The Regents of the University of California
    Inventors: Corey M. Reeves, Brendan M. O'Boyle, Justin A. Hilf, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Steven J. Wittenberger, Oliver C. Loson, Michael D. Bartberger, Brian M. Stoltz